The medicine you buy in a tier-2 pharmacy has meaningful odds of being fake — and no one can check
In 2019 I treated a pneumonia patient who did not respond to a full course of antibiotics. The tablets, sourced from a licensed pharmacy, later tested at a fraction of the labeled active ingredient. The patient survived; my complacency did not. Since then I have studied our pharma supply chain professionally, and the picture is grim: medicines pass from manufacturer through layers of distributors and sub-distributors, with falsified stock entering at the weakest links — often through 'discounted' lots that pharmacies buy in good faith or bad. DRAP's track-and-trace initiative has been announced repeatedly and implemented nowhere at retail scale. Barcode serialization at unit level, verifiable by any pharmacist or patient with a phone, with distributor-level scan checkpoints, is proven technology in other markets. The blocker is coordination, not invention: manufacturers, DRAP, distributors, and pharmacies each wait for the others. A neutral platform-builder with pharma credibility could break the deadlock, starting with the ten most-faked molecules. I am a doctor with the domain map and the motivation; I need builders who can move faster than the committees I sit on.
A high-conviction problem with strong founder-market fit signals. The combination of severe price asymmetry, accessible demographics, and existing infrastructure makes this buildable within 9 months by a small team.
Solutions · 5
Serialized QR at unit level for the 10 most-faked molecules, verified at pharmacy POS with patient SMS fallback
Start narrow and real: the ten most-counterfeited molecules (the antibiotics, PPIs, and cardiac drugs every pharmacist knows), serialized QR per unit pack printed at manufacturer, verified at my counter with a phone scan that burns the code on first sale — resold or cloned codes flag instantly. Patient-side SMS check as fallback for the skeptical. I will run the pilot across my two Peshawar pharmacies and recruit thirty more through the pharmacists' association; we WANT this — fake stock destroys our margins and our names. The manufacturers of genuinely faked brands have anti-counterfeit budgets already; what they lack is a neutral operator connecting print, scan, and enforcement. Dr. Khattak's supply chain map plus my counter-level reality is the founding team this needs.
Distributor checkpoint scanning: catch the fake at the carton level before it reaches 500 pharmacies
Unit scanning at pharmacies catches fakes one pack at a time; carton-level verification at distributor inward catches them 500 packs at a time. Mandate (through the manufacturers' contracts — they have the leverage) that every authorized distributor scans carton aggregation codes at receiving. Stock that skips the scan chain becomes commercially radioactive because the pharmacy app flags unverified supply lineage. I moved pharma stock for eleven years; the suspicious cartons follow patterns any scanning regime would light up immediately.
Start with the diaspora-funded medicines: verification for the drugs overseas families pay for
Families like mine abroad fund parents' chronic medications and live with quiet dread about what is actually in the strip. A subscription where a verified pharmacy fulfills the monthly chronic-med basket — each pack scanned into the family's app with its verification certificate — would be bought by every NHS-working child of Pakistani parents I know. Premium niche, yes, but it funds the scanning infrastructure and creates the first verified-pharmacy network that the mass rollout then rides on.
Independent assay backstop: regional labs spot-test the highest-risk molecules and publish batch results
Serialization verifies the pack traveled legitimately — it cannot verify what is inside the tablet. The backstop layer: regional labs (my Hyderabad lab included) running scheduled HPLC assays on market-sampled batches of the ten target molecules, results published batch-number-searchable — a pharmacist or doctor checks whether batch X of the amoxicillin actually contained amoxicillin at label strength. Substandard batches trigger the serialization network's alerts in reverse. The proficiency-network infrastructure from the diagnostics thread shares equipment, logistics, and credibility with this perfectly; one lab network, two public-health missions. Costing says PKR 8-9M annually covers meaningful national sampling of ten molecules — trivial against the harm.
Pharmacy student army for market surveillance: structured sampling as internship credit
Pharm-D programs require internship hours that students spend photocopying. Partner with universities to make structured market surveillance count: students buy sampled medicines across city zones monthly under protocol, log packaging anomalies against a reference library, and route suspect samples to lab testing. Multan alone graduates hundreds of pharmacy students yearly. The verification platform gets nationwide sampling coverage at near-zero cost; students get real supply-chain forensics experience. My batch would sign up entirely.
Discussion
Pharmacy student: our professor showed us seized counterfeit strips next to genuine ones. Identical to the eye. The idea that consumers should 'buy carefully' is a cruel joke — verification has to be systemic.
NHS pharmacist: I physically carry three months of my parents' cardiac medication from London in my luggage. A verification system would end the pharmaceutical suitcase economy of the entire diaspora.
LHW: in my villages the 'sasti dawai' from the bazaar stall is often the only affordable option. Verification must not price out the poor or they will knowingly choose unverified. Design with this tension in mind.
Critical point. Serialization adds under a rupee per pack at scale — the cost argument against it is manufactured by those who profit from opacity. The poor are the primary victims of fakes, not the beneficiaries of cheap ones.
Hospital procurement sees 'discounted lots' offered constantly. We refuse; smaller hospitals cannot afford to. The economics push fakes exactly where patients are most vulnerable.
Insurance angle nobody mentions: counterfeit-caused treatment failures inflate health claims invisibly. Insurers should be funding verification as loss prevention. Happy to make that case to industry contacts.
My father takes six daily medications in Peshawar. After reading this thread I photographed every strip and sent them to a pharmacist cousin. This is what verification looks like without infrastructure: fear plus family.
Your cousin and I do the same service for dozens of families each. We are the human API for a system that should exist. It is why I co-founded the Build Space — the counter scan replaces the worried WhatsApp.
Rural clinical addendum: my patients' medication failures skew toward exactly the bazaar-stall supply chains the thread maps. The LHW network could carry verification literacy village-deep once the counter-scan exists — our screening visits already discuss medicines. Health systems braid, given the chance.